Gamete donation in assisted human reproduction is a topic that generates considerable debate in bioethics, centered mainly on the discussion of how to accommodate the wishes of the intended parents while respecting the rights of the children, who should always remain the primary focus in the application of these technologies.
It is important to consider the genetic relationship between the different members of the natural family. The existence of a “familial genetic heritage” must be acknowledged, as it connects each person with their parents, siblings, and other family members. Biological inheritance means that every child has an “individual genetic heritage”, unique and distinct from that of their parents. This arises from the combination of maternal and paternal genes following gamete fusion, resulting in the biological inheritance of 50% of the genetic material from each of their progenitors.
Genes determine the inheritance that defines a person’s biological traits. The phenotypic manifestation of these traits can be influenced by other factors, which, while not affecting the DNA sequence, can influence its expression. There is a genetic inheritance to which epigenetics is added. Therefore, in order to better understand the origin of a hereditary trait or the causes of a disease, it is important to be aware of the family genealogical link.
At present, more than 20 years after the completion of the human genome project, many of the nearly 7,000 known human hereditary diseases can be diagnosed through laboratory tests. There are at least around 300 genetic conditions for which tests are available to detect the gene variants carried by a person using samples of their DNA. The list of hereditary disorders that can be analyzed in the laboratory is expanding in a way similar to those detected in newborns through blood spot testing. This knowledge, together with the possibility of establishing family pedigrees, makes it easier to trace the familial origin of many hereditary traits and diseases.
Furthermore, as gamete donation is anonymous and often unlimited or lacking oversight regarding their origin, cases may arise of consanguineous couples who are unaware that they share a common genealogical line. Inbreeding increases the risk that children will inherit homozygous combinations of recessive alleles of genes involved in hereditary disorders. There is ample evidence that diseases due to recessive alleles are those with the highest incidence in instances of consanguinity. Cases of heterozygous donors carrying the same recessive allele implicated in a disease are particularly harmful to potential offspring, due to their status as asymptomatic carriers.
About rights and legislation in cases of gamete donation
Since the introduction of ART, the number of children conceived as a result of these procedures has grown considerably, with an estimated ~10 million children having been born using these technologies worldwide. In 2021, the European Society of Human Reproduction and Embryology (ESHRE) reported more than one million assisted reproduction treatments in 37 European countries. This means that it is urgent to adapt laws to the reality of an ever-growing business.
However, the regulations governing ART vary from one country to another. In general, in the EU, including Spain (Law 14/2006), laws have tended more to favor donor anonymity in the case of heterologous reproduction than to defend the rights of children to know their biological origin. In other words, the donors’ right to privacy has been given more consideration than the children’s right to know their origin. This suggests that donors value anonymity, as this allows them to avoid any kind of responsibility for their “genetic children”, who they have no desire to meet.
Moreover, there is a disparity in legislation between different countries, which is a source of conflict in cases of gamete donation provided by a clinic in one country to meet the demands of a woman or family from another country. For example, in the United Kingdom, information is recorded and stored—which could therefore be provided retrospectively— only in cases of treatment carried out in the country itself. In France, a maximum of 10 donations to different families using the same donor sperm is regulated by law, while in Denmark there is no limit, and in Spain the maximum is 6, etc. There are also differences in retention requirements, in the recording of donor data by ART clinics, and in support in cases of demand for information.
All of this creates multiple problems, prompting calls for the adoption of a common regulation, at least within the EU. In this regard, the Denmark-based European Sperm Bank (ESB), one of the main providers of donor sperm in Europe, has proposed the immediate introduction of a limit of 50 families per donor in the EU common area.
The business of assisted human reproduction clinics
Under existing EU regulations, ART has become a service that generates significant economic benefits for clinics offering these procedures. Thus, the procedure of using sperm samples has a cost that can range between €40,000 and €50,000, depending on the number of children for which the same sample is used. For their part, donors—who supposedly donate altruistically under the euphemism of “financial compensation”—charge around €30 to €60 per session, which, given that multiple sessions are required, can reach up to €1000. As a result, many donors abuse the practice, making repeat donations to ART clinics. It is clear that neither the clinics nor the donors act altruistically, which raises the question: regardless of whether or not donation is altruistic, why does it have to be anonymous?
It is a mistake, however, to consider the donor as the key element in ART procedures, or to suggest that such procedures cannot proceed without them, or that the anonymity and exemption from responsibilities of potential donors makes it easier to attract volunteers. As noted in a report by the Spanish Bioethics Committee (CBE) on January 15, 2020, the reality is that a possible reduction in donations does not mean the demise of ART due to lack of donors, since this has not occurred in countries that have opted to modify donor anonymity regulations.[1]
As a prerequisite, donor suitability must be verified through laboratory tests. However, blood tests may not be sufficient, as they may not reveal the presence of altered genes in certain circumstances. Given the current situation (and in light of the examples that we will discuss later), donor eligibility tests are inadequate, so the utmost care must be taken when accepting volunteers and, in any case, limit the number of donations by the same individual. Restricting the number of children per donor would reduce the risk of transmitting hereditary diseases that are not identified through screening. However, ART clinics, following the example of surrogacy agencies, provide positive data on donor profiles without revealing their identity, which is presumed to be a way to attract more clients.
One important point that will impact the current situation regarding donor anonymity (indicated in the aforementioned CBE report) is the paradigm shift represented by advances in genomics, from a twofold perspective: first, because of how important next-generation sequencing and comparative genomics (GWAS) studies have become for identifying genomic variants associated with the development of genetic diseases, or the risk of acquiring them throughout life, or transmitting them to offspring; and second, due to the trend towards the use and expansion of genomic medicine, with access to large international genealogical and genetic databases. Over time, these advances will make it difficult—even unintentionally—to maintain donor anonymity.
Furthermore, ART is somehow advocated even in the absence of infertility, which encourages parents to reduce reproduction more to fulfilling the desire to be parents than to a mutual, affective, life-generating commitment. The extreme case is surrogacy, banned in the EU (except in Greece and Belgium under certain conditions), in which one or both gametes may come from unknown donors. In these cases, the children become a product, and are even deprived of knowledge of their biological parentage.
Recent sperm donation cases with negative repercussions
The fact is that donor 7069 unknowingly carried a somatic mutation that partially affected his germ tissue but which semen analysis failed to identify. This is really a rare and exceptional case, as this donor has gonadal mosaicism, so that some the sperm stem cells carried a mutation in the p53 gene while others did not. As a result, of the almost 200 children conceived using this donor’s sperm, many inherited the p53 mutation, without the altered allele being detectable prior to any phenotypic manifestation. There are two points to highlight in relation to this matter: one concerning the tests for accepting volunteers as donors; and the other related to the effect of the p53 gene mutation.
First, in the semen analyses, a pathogenic variant may go unnoticed when the donor is asymptomatic and the tests—which are usually performed on DNA from blood samples—fail to detect a somatic mutation present only in part of a specific tissue. In this case, the donor had gonadal (or germline) mosaicism, so that the pathogenic p53 gene mutation must have taken place at some point during organogenesis of the male germline tissue, affecting only part of it. Thus, sperm from the unaffected part of the gonad carry the non-pathogenic p53 allele while the rest carry the altered gene because they originate from the germline stem cells of the affected tissue. The presence of mosaicism in these cells explains the failure to detect them in DNA tests conducted on peripheral blood samples.
Second, there is the specific effect of the mutation. The normal p53 gene is a tumor suppressor that regulates cell proliferation and under normal circumstances prevents the development of any type of cancer. However, mutation of the gene has the opposite effect: it is unable to inhibit cell proliferation and so behaves like an oncogene. The presence of this mutation in children of this donor is a source of cancerous disorders that cause Li Fraumeni syndrome, considered a rare and serious disease that increases the likelihood of developing multiple types of cancer, including sarcomas, breast cancer, leukemia, lymphomas, etc., often at a very young age.
When the first case of Li Fraumeni syndrome was detected in 2023 in a child born using the sperm of donor 7069, the ESB and ESHRE decided to immediately discontinue the use of semen from this donor. In fact, from the outset and in a number of countries, cases with different types of diseases derived from the p53 mutation had been emerging among the offspring of donor 7069. This means that of the 197 children who share the same paternal donor, some will never develop the disease because they inherited the normal version of the p53 gene, while others who inherited the altered gene may develop some form of cancer over time. This case is extremely serious and all families who have had a child conceived using sperm from donor 7069 must be notified in order to adopt immediate preventive measures, including clinical follow-up and regular examinations such as MRI scans, ultrasounds, and other tests performed by specialists.
The responsibility for such cases lies with the ART clinics, which should notify the families. However, in view of the cases that have been emerging, this does not seem to be happening. Despite the seriousness of the matter after this case came to light, and according to the health authorities of several countries, many of the families who received treatment with this sperm (particularly in Denmark and Belgium) have not yet been notified or are unaware of the risk. In Spain, so far three of the children born using gametes from donor 7069 have been affected.
The researchers who uncovered this case of transmission via sperm donation warn about cases like this – hereditary disorders that can remain clinically asymptomatic in donors and be inadvertently passed on to multiple offspring.
Bioethical considerations and actions to be taken
In relation to the practice of heterologous reproduction with sperm donation, the focus should be especially on the children, the direct and often overlooked protagonists in this practice. The United Nations Convention on the Rights of the Child, approved by UNICEF on November 20, 1989, states in Art. 7 that: “The child shall be registered immediately after birth and shall have the right from birth to a name, the right to acquire a nationality and, as far as possible, the right to know and be cared for by his or her parents”, adding in Art. 8 that: “States Parties undertake to respect the right of the child to preserve his or her identity”.
The child’s right to know their biological origin must take precedence over any rights that may be granted to donors, such as the right to privacy, since they are not obliged to participate and altruism can hardly be attributed to them in the voluntary act of donation. In accordance with the Convention on the Rights of the Child, consistent with respect for the dignity and free development of the child’s personality and in order to face any eventuality in relation to their health, the right to know the donor’s identity must prevail.
Furthermore, in cases such as those described, it is necessary to comply with Recommendation 2156-2019 of the Parliamentary Assembly of the Council of Europe on anonymous donation of sperm and oocyte donation, which, balancing the rights of parents, donors and children, promotes the right to access information that would make it possible to trace one’s roots, to know the circumstances of one’s birth, and to have access to certainty of parental filiation. This proposal recommends that EU Member States improve the protection of the rights of all the parties concerned, while focusing on the rights of the donor-conceived person, who is in the most vulnerable position and for whom the stakes appear to be higher. Specifically, it recommends waiving anonymity for all future gamete donations in Council of Europe member States, and prohibiting the use of anonymously donated sperm and oocytes.
Specific stringent measures need to be adopted in the following areas: a) increase the rigor of sperm analyses carried out on potential donors; b) promote common legislation on gamete donation cases across Europe; c) impose restrictions on the total number of children per donor across Europe, and require ART clinics to comply with legal and donor registration standards; (d) create an international registry to track and document the number of children conceived through donation; and (e) remove donor anonymity.
From a bioethical perspective, it is clear that sperm donation, in the conditions under which it is currently carried out, adds yet another problem to the many resulting from ART. The inheritance of undetected diseases in children conceived using the same donor is added to the effects of hormonal treatments for egg donors; risks of consanguinity; health problems in children due to uncontrolled epigenetic modifications; and all aspects concerning the instrumentalization of embryos, which may be frozen, selected, discarded, or used in research. This constitutes a whole set of problems and risks that must be considered and about which families seeking treatment in ART clinics must be advised, prior to providing informed consent.
Nicolás Jouve
Professor Emeritus of Genetics at the University of Alcalá
Member of the Bioethics Observatory of the Catholic University of Valencia
References:
[1] Report of the Spanish Bioethics Committee on the right of children born using assisted human reproduction techniques to know their biological origins, PDF: Link to the report in the CBE; Link to the report in CiViCa
[2] Marquès L, Batlle-Masó L, Alcoceba E, Lara S, Aguiló-Cucurull A, Gil-Serrano J, Guilarte M and Colobran R Transmission of F12-related hereditary angioedema through a sperm donor. Front. Immunol. 17 (2026) 1799395.